What is Emergent Biosolutions's SG&A?

Emergent Biosolutions (EBS) reported SG&A of $46.6M in Q1 2026.

How has Emergent Biosolutions's SG&A changed year-over-year?

Emergent Biosolutions's SG&A decreased by 11.1% year-over-year, from $52.4M to $46.6M.

What is the long-term trend for Emergent Biosolutions's SG&A?

Over 4 years (2021 to 2025), Emergent Biosolutions's SG&A has grown at a -14.5% compound annual growth rate (CAGR), from $348.7M to $186.1M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Emergent Biosolutions EBS SG&A

SG&A at other companies

Thermo Fisher ScientificTMO

$2.18B+5.0%

Regeneron PharmaceuticalsREGN

$647.7M+2.3%

Amneal Pharmaceuticals, Inc.AMRX

$138.86M+17.4%

Collegium Pharmaceutical, Inc.COLL

$86.35M+13.0%

Opko HealthOPK

$48.61M-17.7%

West Pharmaceutical ServicesWST

$99.5M+13.1%

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's SG&A?: Emergent Biosolutions (EBS) reported SG&A of $46.6M in Q1 2026.
How has Emergent Biosolutions's SG&A changed year-over-year?: Emergent Biosolutions's SG&A decreased by 11.1% year-over-year, from $52.4M to $46.6M.
What is the long-term trend for Emergent Biosolutions's SG&A?: Over 4 years (2021 to 2025), Emergent Biosolutions's SG&A has grown at a -14.5% compound annual growth rate (CAGR), from $348.7M to $186.1M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.